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ABSTRACT:  Despite a long history of successful use, routine application of some 1 
anticoagulant rodenticides (ARs) may be at a crossroad due to new regulatory guidelines 2 
intended to mitigate risk.  An adverse outcome pathway for ARs was developed to identify 3 
information gaps and endpoints to assess the effectiveness of regulations.  This framework 4 
describes chemical properties of ARs, established macromolecular interactions by inhibition 5 
of vitamin K epoxide reductase, cellular responses including altered clotting factor processing 6 
and coagulopathy, organ level effects such as hemorrhage, organism responses with linkages 7 
to reduced fitness and mortality, and potential consequences to predator populations.  Risk 8 
assessments have led to restrictions affecting use of some second-generation ARs (SGARs) in 9 
North America.  While the European regulatory community highlighted significant or 10 
unacceptable risk of ARs to non-target wildlife, use of SGARs in most EU member states 11 
remains authorized due to public health concerns and the absence of safe alternatives.  For 12 
purposes of conservation and restoration of island habitats, SGARs remain a mainstay for 13 
eradication of invasive species.  There are significant data gaps related to exposure pathways, 14 
comparative species sensitivity, consequences of sublethal effects, potential hazards of greater 15 
AR residues in genetically-resistant prey, effects of low-level exposure to multiple 16 
rodenticides, and quantitative data on the magnitude of non-target wildlife mortality.  17 
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HISTORY AND USE OF ANTICOAGULANT RODENTICIDES 18 
Anticoagulant rodenticides (ARs) are used worldwide for vertebrate pest control in urban and 19 
suburban settings, agriculture, and island restoration projects.  These compounds block the 20 
vitamin K cycle and impede synthesis of active forms of several blood clotting factors (II, 21 
VII, IX and X) necessary for hemostasis.  Their discovery and development began with Karl 22 
Paul Link’s investigations of “bleeding disease” in cattle consuming improperly cured sweet 23 
clover.
1
  By 1940, Link had isolated, crystallized and synthesized dicumarol (similar in 24 
structure to vitamin K), that led to the synthesis of over 100 analogs with hemorrhagic 25 
properties, including the highly potent compound number 42, warfarin.  By the early 1950’s, 26 
warfarin was registered as a pesticide to control rats and mice, and its clinical application as 27 
the “blood thinner” Coumadin® was approved for medicinal use, with U.S. President Dwight 28 
Eisenhower being a prominent treatment recipient in 1955. 29 
In the opening sentence of their review, Hadler and Buckle
2
 state, “Few modern pesticide 30 
groups have such a long history of successful use as the anticoagulant rodenticides”, that 31 
continues to this very day.  These compounds revolutionized vertebrate pest control.  The first-32 
generation anticoagulant rodenticides (FGARs; e.g., warfarin, chlorophacinone, diphacinone) 33 
require multiple feeds to cause death in rodents, but their use resulted in the emergence of 34 
genetic resistance in rats and house mice.  The more potent and moderately persistent 35 
“superwarfarin” second-generation anticoagulants rodenticides (SGARs; e.g., brodifacoum, 36 
difethialone, bromadiolone, difenacoum, flocoumafen) were developed to overcome resistance 37 
and require only a single bait feeding to cause death in target rodent species.  Although national 38 
and global AR market data are “confidential business information”, estimates of AR use are 39 
illustrated by (i) a report indicating production or import of 1764 kg of active ingredient of four 40 
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ARs in the U.S. in 1997,
3
 (ii) a market analysis suggesting that U.S. homeowners spent $110 41 
million on rodenticides in 2005,
4
 (iii) the sale of 454 metric tons of formulated product in 42 
California for agricultural purposes in 2007,
5
 (iv) use of approximately 544 metric tons of bait 43 
containing AR by local authorities in the UK in 2001,
6
 and (v) application in over 700 of 1,527 44 
invasive species eradication projects worldwide.
7 
  45 
Despite their evident success in agriculture and conservation-based activities, continued 46 
use of some SGARs for control of commensal rodents in urban, suburban, rural and even 47 
agricultural settings may be at a crossroad.  It is well-recognized that AR application is the only 48 
current method for rapid and effective eradication of “established ” rodent infestations.8,9  Large 49 
scale applications of ARs have also been used to control population peaks of small mammals 50 
(e.g., rodent plagues) exhibiting demographic cycles.
10
  However, it is also apparent that ARs are 51 
responsible for many unintentional exposures of children (mostly minor and asymptomatic), 52 
companion animals and non-target wildlife, and a small fraction of such exposures result in 53 
fatalities.
11-15
  New restrictions have been placed on the use of some AR baits to mitigate 54 
risk.
13,16
  Herein, we present an AR adverse outcome pathway (AOP), and briefly review risk 55 
assessment data, recent regulatory changes on AR use in North America and elsewhere, risk 56 
mitigation, conservation uses of ARs, and unsolved issues on exposure and toxicity as they relate 57 
to predatory birds and mammals.  58 
 59 
ADVERSE OUTCOME PATHWAY FOR ANTICOAGULANT RODENTICIDES 60 
An AOP is a conceptual framework portraying existing knowledge as a logical sequence of 61 
processes linking a direct molecular initiating event to an adverse effect across multiple levels of 62 
biological organization, which is relevant in risk assessment.
17-19
  In an ecological context, 63 
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population-level responses are most germane for natural resource management, although for 64 
species of special conservation status (e.g., threatened or endangered, or highly valued to a 65 
particular stakeholder group), effects at the level of the individual may have important 66 
population consequences.  The AOP framework has application in predictive and regulatory 67 
toxicology, particularly for well-studied chemicals like ARs (Figure 1).   68 
 69 
Figure 1.  A proposed Adverse Outcome Pathway for anticoagulant rodenticides in non-target 70 
predatory wildlife.  71 
Chemical Properties and Macromolecular Interactions.   Anticoagulant rodenticides have 72 
low solubility in water and low volatility.
20
  For all FGARs, and the SGARs bromadiolone and 73 
flocoumafen, octanol:water partition coefficients (log Kow) are less than 5, and thus have low or 74 
moderate bioaccumulation potential.  In contrast, the log Kow’s for the SGARs difethialone, 75 
difenacoum and brodifacoum range from 5.17 to 8.50, and thus these compounds exhibit greater 76 
potential for bioaccumulation.  Based upon studies examining the toxicity of 4-hydroxycoumarin 77 
and indandione ARs to sensitive and resistant strains of rats, bulky lipophilic extensions of the 78 
acetonyl side chain contribute to their increased affinity to the active site of vitamin K epoxide 79 
reductase, and compounds having tetrahydronaphthyl side-chains (e.g., difenacoum) are more 80 
resistant to biotransformation.
21
  In contrast, FGARs are readily hydroxylated (notable 81 
exceptions include raptorial birds
22
) to inactive metabolites that are excreted.
23
  Using solid-state 82 
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structures of coumatetralyl and chlorophacinone as input geometries, computational chemistry 83 
efforts were conducted for 13 ARs.
24
  Structure-activity relationship models suggest that toxicity 84 
is related to the length and hydrophobicity of the side chain at carbon 13, with the most active 85 
compounds having greater volume and bulky lipophilic groups in this activity domain (Figure 86 
2).
21,24
   87 
 88 
Figure 2.  Structure of the first-generation anticoagulant rodenticide warfarin and the second- 89 
generation anticoagulant rodenticide brodifacoum, illustrating side chains (red) of the activity 90 
domain attached at carbon 13 (blue *).  91 
Anticoagulant rodenticides bind tightly to and inactivate vitamin K epoxide reductase 92 
(VKOR), an integral membrane protein found on the rough endoplasmic reticulum in 93 
hepatocytes, and VKOR is also present in cells of other tissues.
25
  Catalytic activity of VKOR is 94 
necessary for the reduction of both vitamin K epoxide and vitamin K to vitamin K hydroquinone, 95 
the biologically active form required for the γ-glutamyl carboxylation of glutamine residues 96 
(Figure 3) on clotting factors II (prothrombin), VII, IX and X.  The primary amino acid sequence 97 
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and the gene encoding VKOR have been well-studied, and the membrane topology and active 98 
site (cysteine sulfhydryl groups at residues 132 and 135 and warfarin binding site at tyrosine 99 
139) have been modeled (Figure 4).
25
  Inhibition of VKOR activity by warfarin, and other 100 
anticoagulant rodenticides, limits the formation of vitamin K hydroquinone resulting in under-101 
carboxylated clotting factors (e.g., des-γ-carboxy prothrombin)26 that will not assemble on cell 102 
surfaces to form a clot (viz., molecular initiating/anchor event in AOP, Figures 1 and 3).  103 
Vitamin K1 (phylloquinone) is an antidote to AR intoxication, and has long been used to treat 104 
people, companion animals, and occasionally wildlife.
27
  Its administration results in the 105 
formation of the vitamin K hydroquinone by DT-diaphorase, a vitamin K cycle enzyme which is 106 
resistant to ARs,
25
 thus restoring carboxylation of clotting factors.  107 
 108 
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Figure 3.  Diagram of the vitamin K cycle showing two anticoagulant rodenticide (AR) sensitive 109 
vitamin K epoxide reductase (VKOR) reactions and a warfarin-insensitive VKOR that reduces 110 
vitamin K to the biologically-active vitamin K hydroquinone.  Without adequate vitamin K 111 
hydroquinone, γ-glutamyl carboxylase lacks substrate to adequately carboxylate clotting factors 112 
II, VII, IX and X (adapted from Tie and Stafford 2008).
25
  113 
 114 
Figure 4. Primary structure and membrane topology of the anticoagulant rodenticide-sensitive 115 
vitamin K epoxide reductase (adapted from Tie and Stafford 2008).
 25
  All single letter amino 116 
acid abbreviations follow IUPAC nomenclature.  The warfarin binding site is Y139 (orange) and 117 
the active redox sites are C132 and C135 (white).  The most thoroughly studied mutation for 118 
warfarin resistance is at Y139; common mutations include substitutions of S, C, and F, for Y.  119 
Other common mutations that afford warfarin resistance are indicated in yellow.
9,30
     120 
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 Widespread use of the warfarin resulted in selection for warfarin-resistant rats associated 121 
with reduced or reversible binding to VKOR.
21
  Mutation of the VKOR gene coding tyrosine 139 122 
and amino acid substitutions at other locations can confer resistance to FGARs
28-30
 and some 123 
SGARs.
9
  There is also evidence that resistance can be conferred by other mechanisms including 124 
increased AR clearance associated with enhanced CYP3A2 expression.
31 125 
Cellular Responses.  Blood coagulation is the central component of hemostasis.
32
  At the 126 
cellular level, coagulation is initiated through an extrinsic pathway (tissue factor pathway) with 127 
the generation of tissue factor that complexes with carboxylated factor VII, which in turn 128 
activates factor X in the common pathway, and to a lesser degree in the intrinsic pathway 129 
(contact activation pathway), where factor IX is activated.  Factors XI and XII of the intrinsic 130 
pathway are absent altogether in several avian species.
33
  Through the common pathway, a 131 
number of reactions lead to the activation of prothrombin to form thrombin.  Thrombin cleaves 132 
circulating fibrinogen into soluble fibrin monomers that polymerize, and it also activates factor 133 
XIII, which in the presence of calcium cross-links the polymer to form insoluble fibrin.  In the 134 
classic cascade model, thrombin formation is markedly amplified through the intrinsic pathway.  135 
However, in vivo hemostasis is now better described by a cell-based model, in which stages 136 
overlap and are controlled by cellular components rather than protein levels and kinetics,
34
 with 137 
alterations in factor IX having greatest effects on thrombin generation and clotting.
35
   138 
Measurement of clotting time (e.g., prothrombin time, partial thromboplastin time, 139 
activated partial thromboplastin time) of citrated plasma has long been used as a routine 140 
diagnostic tool for AR intoxication in companion animals and people.  Its application to 141 
diagnose AR intoxication in captive and free-ranging wildlife is rare.
36
 Clotting time assays 142 
are sensitive, precise, inexpensive, linked to the pathogenesis of toxicity, and have 143 
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applicability as biomarkers of exposure and effect in both controlled studies and field 144 
monitoring (Figure 1).  In wildlife, lengthening of prothrombin time by more than 25%
37, 38
 or 145 
two standard deviations above baseline values
39
 is suggestive of anticoagulant exposure, and 146 
best confirmed by analytical detection of AR residues in blood or tissue.   147 
Following exposure to warfarin and other ARs, there is a lag period of one to several 148 
days before coagulopathy (detectable with biomarkers) becomes apparent.  This is because 149 
fully-carboxylated functional clotting factors, with half-lives ranging from 6 to 120 hours
40
 150 
support hemostasis, but once cleared clotting is impaired (viz., key event in AOP, Figure 1).  151 
This lag period is well-documented in people, companion animals, laboratory rodents, and 152 
even raptorial birds.
41-43
  Upon termination of AR exposure, coagulopathy can be resolved in a 153 
matter of days or weeks,
41,43
 but VKOR activity may remain partially inhibited for weeks to 154 
months, reducing reserve capacity to synthesize vitamin K, and thus rendering animals highly 155 
sensitive to subsequent AR exposures.
44
   156 
Multiple Organ System Responses.  Animals can exhibit massive blood loss and succumb from 157 
fatal hemorrhage, but lethality can also result from small microscopic bleeds resulting in 158 
localized ischemia, hypoxia and cell death at vital sites (e.g., brain, heart, liver).
12,39,42
  Aside 159 
from AR effects on hemostasis, there are many less well-established responses related to the 160 
impairment of the vitamin K cycle (viz., plausible linkage in AOP, Figure 1).  For example, 161 
pediatric warfarin therapy can reduce bone density and increase incidence of fractures due to 162 
undercarboxylation of osteocalcin, the protein incorporating calcium into bone,
45
 although in the 163 
single study conducted in SGAR-exposed predatory birds, no such effect was found.
46
  Warfarin 164 
has been shown to exert anti-inflammatory effects,
47
 possibly by altering signal transduction,
48
 165 
and also affect cell proliferation by inhibiting vitamin K-dependent growth factors.
49
  In addition, 166 
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the indandione rodenticides chlorophacinone and diphacinone may also affect cellular energy 167 
generation by uncoupling oxidative phosphorylation.
50
 168 
 Hemorrhage associated with coagulopathy can be spontaneous, but is often initiated and 169 
certainly exacerbated by trauma, which is not that unusual in free-ranging wildlife.  A 170 
comprehensive review
11
 provides 50 citations of affected sites and signs of hemorrhage in 171 
various organ systems (e.g., integument, musculoskeletal, respiratory, renal, gastrointestinal, 172 
reproductive, central nervous system) associated with sublethal and fatal AR poisoning in 173 
people.  A similar tabulation of affected sites and signs has yet to be compiled for non-target 174 
wildlife, although detailed results of necropsies do appear in some reports.
12,39,42,51,52
  Overt signs 175 
often include bruising, bleeding from the mouth, nares, rectum, cloaca, and talons, and blood in 176 
droppings, scat and urine.  Skin, mucus membranes, muscle and viscera can appear pale due to 177 
blood loss.  At necropsy, affected sites often include skin, muscle, alimentary tract, peritoneal 178 
cavity, kidney, and heart pericardium.  Assessment of such effects in animals found dead may be 179 
hampered due to deterioration of organs and tissues, and hemorrhage due to freezing of carcasses 180 
prior to necropsy.
53
  There can be excessive bleeding from superficial wounds and hemorrhage 181 
from multiple sites.  Blood loss accompanying AR exposure is a function of dose and frequency 182 
of exposure, and can range from mild to severe with classification of an individual as being 183 
anemic, and is easily quantified in vivo (e.g., reduced number of circulating red blood cells, 184 
increased reticulocyte counts from stimulation of hematopoiesis, and decreased 185 
hematocrit).
12,27,39,41,54,
  Blood loss can result in metabolic acidosis, tachycardia, and 186 
hypovolemic shock,
54
 causing changes in tissue perfusion, organ dysfunction, and tissue 187 
necrosis.  188 
Whole Animal Responses.  At the organismal level, inter-individual variation seems to have a 189 
12 
 
significant role in AR toxicosis.
12
  Lethargy and abnormal posture are overt apical responses 190 
frequently observed in toxicity studies, and often described in AR-exposed wildlife undergoing 191 
rehabilitation.  Body condition and weight loss are mentioned in many reports, and a significant 192 
negative relation between AR residues and body condition has been found in stoats (Mustela 193 
ermine) and weasels (Mustela nivalis).
55
  Furthermore, an association between notoedric mange, 194 
mortality and AR exposure has been described in bobcats (Lynx rufus) residing in urban areas in 195 
southern California,
56
 although such relationships may be correlative rather than causal.  For 196 
example, animals suffering from mange may be forced to forage in poor habitat in closer 197 
proximity to people.  Direct toxic effects of ARs on reproduction in laboratory mammals, 198 
livestock and free-ranging raptorial birds are somewhat equivocal,
57-60
 although the European 199 
Chemicals Agency classifies some ARs as reproductive toxicants.
61
 Clearly, such observations 200 
and data are difficult to translate into measureable consequences affecting the fitness (i.e., 201 
survival and reproduction) of free-ranging wildlife.  Indirect effects, such as altering availability 202 
of rodent prey species, could certainly affect predator-prey dynamics.   203 
Population Responses.  Although rodenticides are widely used, effects of ARs at the population 204 
level of predatory birds and mammals have not been established.  Of the published reports that 205 
examine exposure and unintentional wildlife mortality,
12,51,52, 62-68
 definitive diagnosis of 206 
poisoning (i.e., post-mortem signs of hemorrhage, independent of trauma, coincident with the 207 
detection of rodenticide residues in liver) generally accounts for but a small fraction of exposures 208 
(perhaps <10%),
12,60
 with exceptions.
51,67
  As pointed out 15 years ago, there is no evidence that 209 
rodenticide use causes large-scale population declines of predatory and scavenging birds.
69
  210 
However, AR exposure does have the potential to cause additional mortality affecting 211 
populations “already experiencing critical limitations”70 (viz., plausible linkage in AOP, Figure 212 
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1).  Furthermore, for long-lived predators or scavengers with low reproductive rates (K-213 
strategists), death of a few individuals could theoretically affect local populations on a temporary 214 
basis.  In a contemporary effort to examine potential population consequences of ARs, hepatic 215 
residues and associated signs of intoxication were examined in a dataset of 270 birds of prey 216 
from Canada.
71
  Using an additive approach for SGAR residues (bromadiolone + brodifacoum + 217 
difethialone; viz., toxic units) and logistic regression plots to predict the probability of the death 218 
of a bird with a liver residue of any given magnitude, it was suggested that a minimum of 11% of 219 
the great horned owl (Bubo virginianus) population in Canada is at risk of being directly killed 220 
by SGARs.  That assessment, however, was based on exposure levels of great horned owls in 221 
areas with high human population density and rodenticide use, and may not apply across broad 222 
areas of the Canadian landscape.  Regardless, the prediction that 11% of the population of an 223 
abundant K-strategic species is at risk from a single stress factor should be carefully considered, 224 
and in some circumstances may not be acceptable to natural resource managers.   225 
 There have been some instances of label-recommended or permitted AR use that have 226 
resulted in mortality incidents involving species of special conservation status or those afforded 227 
special protection.  For example, mortality incidents have been reported for weka (Gallirallus 228 
australis; vulnerable-IUCN Red List) in New Zealand,
72
 red kites (Milvus milvus; near 229 
threatened-IUCN Red List) in Britain and France,
73,74
 and bald eagles (Haliaeetus leucocephalus; 230 
Least Concern-IUCN Red List but safeguarded by The Bald and Golden Eagle Protection Act) in 231 
the U.S.
75
  There are less definitive incidents involving the San Joaquin kit fox (Vulpes macrotis 232 
mutica; U.S. Federally-endangered species ) and northern spotted owl (Strix occidentalis 233 
caurina; near threatened-IUCN Red List).
76
  The status of barn owl (Tyto alba) populations in 234 
southwestern British Columbia, Canada was recently up-listed to threatened due to many 235 
14 
 
stressors including poisoning by rodenticides.
65,77
  In such circumstances, an organismal 236 
response (i.e., death of an individual of a threatened or endangered species), rather than a 237 
population-level response, may be considered an anchoring event
17
 in an AOP.  Nonetheless, 238 
incidental take of a few individuals of a Federally-listed species may be permitted under current 239 
regulations, as is the case for the black-footed ferret (Mustela nigripes), gray wolf (Canis lupus) 240 
and northern aplomado falcon (Falco femoralis) with Rozol® Prairie Dog Bait 241 
(chlorophacinone) application.
78
  242 
 243 
ANTICOAGULANT RODENTICIDE RISK ASSESSMENT FOR PREDATORS 244 
Registration and Regulation.  The use of pesticides requires detailed regulatory evaluations 245 
that ensure the compound does not pose an unacceptable risk to people or the environment.  Such 246 
assessments take into account economic, social and environmental costs and benefits, and 247 
general requirements (e.g., new products, re-registrations, sale, distribution, use, etc.) of the 248 
vertebrate pesticide registration process.
79
  Adverse reactions of non-target species to pesticide 249 
active ingredients are predicted from toxic effects observed in surrogate species exposed in the 250 
laboratory.  In the U.S., Canada and Europe, the required data have been generated on standard 251 
toxicological endpoints in traditionally used test species (e.g., bobwhite quail, Colinus 252 
virginianus and mallard, Anas platyrhynchos), and occasionally other species (historically, 253 
mustelids).  In New Zealand, an array of introduced mammals has been included in registration 254 
studies for purposes of examining AR efficacy.  These data, coupled with field observations, and 255 
residue and fate information, are used by regulatory agencies, industry and other entities 256 
conducting ecological risk assessments.
79
   Registered products undergo periodic review, which 257 
can be triggered by new findings and unexpected observations following their use.  258 
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 In the U.S., the use profile (e.g., application site and method, formulation, pest species) of 259 
FGARs includes urban, suburban and rural areas, and agricultural fields, with initial product 260 
registrations for warfarin dating back to 1950, followed by diphacinone in 1960, and 261 
chlorophacinone in 1971.
80
  Registration of SGARs in the U.S. occurred much later 262 
(brodifacoum 1979, bromadiolone 1980, difethialone 1995),
80
 and the use profile was far more 263 
restrictive and did not include agricultural fields (some SGARs are permitted for agricultural use 264 
in Europe).  Product registrations for both FGARs and SGARs have been granted for 265 
conservation purposes, including eradication of invasive species on islands.
79,81
  266 
   Long after the initial registration of several FGARs and SGARs in the U.S., multiple non-267 
target wildlife mortality incident reports,
80
 several peer-reviewed publications,
52,62, 63,72, 82
 and 268 
public interest at the time of the Re-registration Eligibility Decision
83
 were the impetus to 269 
undertake a comparative risk analysis of rodenticides.
80
  Using a multi-attribute rating technique 270 
(e.g., dietary risk quotient for primary exposure, percent mortality in secondary exposure, active 271 
ingredient retention time in blood and liver), the SGARs brodifacoum and difethialone were 272 
identified as posing the greatest potential risks to predatory and scavenging birds and mammals 273 
that feed on poisoned target and non-target animals.  Attempts to evaluate the risk of 274 
brodifacoum using probabilistic methods (i.e., dietary dose, uptake and depuration models, 275 
probability of encountering contaminated prey) were hampered by data gaps and major 276 
uncertainties.
84
  Deterministic evaluations led the U.S. EPA to request registrants to voluntarily 277 
withdraw certain ARs from the marketplace.
76
   278 
 In the U.S. EPA’s comparative risk analysis, the FGARs seemed to be less hazardous to 279 
both target and non-target species.
80
  Some of this analysis relied on acute toxicity data.  280 
However, an acute exposure scenario is neither appropriate nor environmentally relevant (i.e., 281 
16 
 
may underestimate environmental risk) as FGARs require multiple days of exposure to evoke 282 
toxicity.
85
  Additionally, more FGAR bait is needed to achieve the same level of pest control as 283 
with SGARs, and thus the number of toxic units in the environment at the time of application is 284 
likely to be the same or greater.  Furthermore, the development of FGAR resistance in 285 
commensal rodents may result in greater potential for exposure of and risk to predatory species.    286 
Risk Mitigation Measures.  In 2008, the U.S. EPA instituted measures to mitigate some non-287 
target risks of SGARs.  These included new requirements on points of sale and distribution, and 288 
package size, to impede purchase by residential homeowners, and product labeling to permit use 289 
in and around agricultural buildings, but not human residences.
13 
 New bait station requirements 290 
were also instituted to minimize exposure of children, pets, and non-target wildlife.  Additional 291 
exposure modeling and quantitative risk assessments to evaluate direct bait ingestion (primary 292 
exposure) and consumption of prey containing AR residues (secondary exposure) were 293 
undertaken.
4
  Based on toxicity and toxicokinetics, risk quotients for direct bait consumption 294 
indicated that under some exposure scenarios both SGARs (brodifacoum, difethialone) and 295 
FGARs (warfarin, chlorophacinone) exceeded levels of concern for non-target birds and 296 
mammals.  Consumption of SGAR-exposed prey also exceeded levels of concern for predatory 297 
birds and mammals.  While consumption of FGAR-exposed prey posed a hazard for non-target 298 
mammals, levels of concern were rarely exceeded for birds.
4
  In some use scenarios (e.g., 299 
Rozol® for control of prairie dogs, Cynomys ludovicianus), label requirements even state that 300 
applicators must make multiple follow-up visits after application to remove dead or dying target 301 
species to mitigate hazard to non-target scavengers and predators.
86
  Such practices to reduce 302 
potential AR exposure of predators may not always be followed.
86,87 
 At the Federal Insecticide, 303 
Fungicide, and Rodenticide Act Scientific Advisory Panel hearing in November 2011, some 304 
17 
 
shortcomings of this screening-level risk assessment were identified, including data quality and 305 
interpretation, and overreliance on unrealistic worst-case scenarios.
88
 306 
 The U.S. EPA risk mitigation decision has resulted in actions to cancel consumer uses of 307 
some non-compliant rodenticides (some products containing warfarin, brodifacoum, and 308 
difethialone that failed to meet US EPA safety measures) though over 30 AR products remain 309 
available that meet protective standards.
89
  Notably, the active ingredient of some replacement 310 
compounds (e.g., acute vertebrate pesticides such as bromethalin) lack diagnostic tests and 311 
antidotes.  In the U.S., a few states conduct additional regulatory review of pesticides, and the 312 
State of California will be restricting the use of SGARs to certified pesticide applicators as of 313 
July 1, 2014.
90
  The U.S. EPA and the Canadian Pesticide Management and Regulatory Agency 314 
collaborate to harmonize pesticide regulations in North America.  Risk mitigation measures 315 
similar to those proposed by the U.S. EPA are now in effect in Canada, with some minor 316 
variances (e.g., bromadiolone can be applied by registered users along fence lines within 30 m of 317 
buildings).
16,91
  318 
 In Europe, a recent review (European Chemicals Agency) under the European 319 
Community Biocidal Products Directive (98/8/EC)
92
 has highlighted significant or unacceptable 320 
risk of primary and/or secondary poisoning of birds and non-target mammals from some SGARs 321 
used as biocides.
55,64,67,93-95
  However, under this Directive the compounds were still authorized 322 
for use because they are deemed essential for human hygiene and public health, and appropriate 323 
alternatives are not at hand.  In 2012, a new EU Biocidal Products Regulation (528/2012)
96
 was 324 
adopted with similar criteria for authorization.  Under this regulation, all SGAR use will be re-325 
evaluated by the end of 2017.  Requirement for any mitigation measures to reduce risk to non-326 
target exposure is at the discretion of individual EU member states.  For example, in the United 327 
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Kingdom, SGAR use has been widespread in both urban and rural environments.
6,97-99
  328 
Brodifacoum, flocoumafen and the more recently licensed difethialone have until now been 329 
restricted to indoor use because of their perceived risk of causing primary and secondary 330 
poisoning in non-target species; other SGARs and FGARs have until now been licensed for 331 
indoor and outdoor use.  There is prevalence of SGAR application in agricultural holdings
68
 with 332 
concomitant widespread exposure in rural areas of a range of non-target avian and mammalian 333 
predators .
68,70,99-101
   A recent UK review related to the primary and secondary risks posed by all 334 
SGARs concluded that there was insufficient scientific evidence to distinguish between any of 335 
the SGARs in terms of their risk to non-target species.
102
  As a result, it is proposed that UK 336 
authorizations will change during 2014 or beyond, such that all SGARs may be used outdoors 337 
and there will be a stewardship program fostering practices to minimize exposure of non-target 338 
species.  Other EU member states may adopt alternate mitigation measures.  For example, 339 
discussions on outdoor use of SGARs in The Netherlands are on-going and it is proposed that 340 
SGARs may be used outdoors by certified personnel, in combination with certified Integrated 341 
Pest Management.   342 
In New Zealand, brodifacoum typically has been the SGAR of choice for controlling 343 
rodents, all of which are invasive non-native species.  However, repeated use of brodifacoum on 344 
the two main islands has been associated with substantial contamination of wildlife and game 345 
species, and secondary poisoning of non-target species.
103
  As a result, there has been use of low-346 
residue alternatives (cholecalciferol) for control of possums and rodents, registration of para-347 
aminopropiophenone for control of larger pest species (stoats and weasels), and exploration of 348 
some toxicant combinations (e.g., FGARs + cholecalciferol) for control of rodents.
104,105
 349 
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Special Considerations for Use in Conservation.  Anticoagulant rodenticides have been used 350 
extensively for the control and eradication of introduced and invasive species,
7,106,107
 particularly 351 
for island ecosystems.  The use of these compounds in such settings is logistically complex and 352 
expensive, with the theoretical restoration benefit outweighing the risk of non-target species 353 
mortality.
81
  In contrast to standard use of ARs for commensal or agricultural rodent control, 354 
special regulatory attention is given to the application of these compounds for conservation 355 
purposes to restore habitat for native species.  As an example of conservation use, a Special 356 
Local Needs pesticide registration for aerial broadcast of 0.005% diphacinone bait was 357 
undertaken in Hawaii to control rodents and wild pigs (Sus scrofa) in native ecosystems.  Hazard 358 
was evaluated using both deterministic
108
 and probabilistic
109 
methods for the endemic Hawaiian 359 
hawk (Buteo solitarius), short-eared owl (Asio flammeus sandwichensis), and honeycreeper 360 
(Melamprosops phaeosoma).  These evaluations found that the quantity of tissue that would have 361 
to be consumed by a predator in acute and subacute exposure scenarios was great (often 362 
exceeding the weight of the bird); thus, the risk to evoke lethality or prolonged clotting time was 363 
low.  As previously mentioned, an acute exposure scenario is neither appropriate nor 364 
environmentally relevant for assessing risks of FGARs.
85
  These assessments using data from 365 
traditional wildlife test species may have underestimated risk as recent studies
 
have demonstrated 366 
that raptors are far more sensitive to diphacinone than previously thought.
39,42,43
  Application of 367 
American kestrel (Falco sparverius) and Eastern screech-owl (Megascops asio) toxicity data for 368 
diphacinone in previous deterministic assessments,
4,108
 and in probabilistic assessments,
39,110
   369 
suggest greater hazard to predatory birds than previously realized.  Nonetheless, FGARs are 370 
believed by some to be much less hazardous (perhaps by an order of magnitude)
72
 than SGARs, 371 
presumably due to their shorter half-life in tissues and multi-day exposure required to cause 372 
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toxicity.  These findings also demonstrate the importance of dose-response relationships, 373 
including use of toxic reference values,
43,110
 to link a biomarker (clotting time) or tissue residues 374 
to an adverse effect.  Such data are of value to natural resource managers.  However, it is 375 
difficult to extrapolate the internal dose with effects across species and multiple studies.  The 376 
AOP construct provides the basis to fill in these data gaps that may be used to help model and 377 
interpret dose-response relationships.
17
  378 
 379 
UNSOLVED ISSUES  380 
There are significant unknowns related to exposure and effects to predatory wildlife associated 381 
with use of ARs.  Among these are basic and applied data needs to supplement risk assessments.  382 
Some of these data are best derived from controlled exposure trials using captive animals, while 383 
other information can only be generated from field observations and hypothesis-driven eco-384 
epidemiological studies, and even a combination of these activities.  385 
Exposure Pathways.  While there are many conceptual models,
108,109
 there are limited empirical 386 
field data detailing AR exposure pathways and compound transfer to predatory wildlife per se.  387 
This shortcoming was noted in the regulatory review of a probabilistic risk assessment for 388 
brodifacoum.
84
  Many studies have focused on consumption of poisoned rodents.  The exposure 389 
pathway starts with AR bait placement and its ingestion by target species.  Secondary exposure 390 
of predatory and scavenging wildlife occurs exclusively through their diet, which at times can be 391 
quite variable.  For example, a recent investigation identified the primary target organism, 392 
Norway rats (Rattus norvegicus), as the most important source of SGARs for several species of 393 
owls at farms in British Columbia, Canada.
91
  Small mammals, songbirds and invertebrates were 394 
also components of the exposure pathway for secondary consumers in this study.
91
   395 
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 Exposure pathways can be complex, with non-target predators encountering a combination 396 
of ARs.  Notably, tissues analyzed from mortality incidents document exposure to multiple 397 
SGARs to varying degrees,
 12,51,52,56,62,63,65,68,71,100 
 and occasionally even combinations of FGARs 398 
and SGARs.
51,56
 That suggests that some predators may reside and forage opportunistically at the 399 
interface of urban/suburban/rural and agricultural settings.  For example, rats and non-target 400 
small mammals (but not house mice) exposed to SGARs while indoors may move outdoors from 401 
unsealed buildings, and can travel considerable distances before becoming available to 402 
predators.
91,111
  Likewise, the foraging range of many predators changes with season.  For 403 
example, commensal rats seem to be a significant source of seasonal rodenticide exposure for 404 
polecats (Mustela putorius) that favor farmyards during fall and winter months.
100,112
  405 
Accordingly, estimating risk to non-target predatory species by extrapolation of toxicity data 406 
from single-compound controlled laboratory and pen studies remains exceedingly difficult.  As 407 
demonstrated in highly inbred laboratory rats, combined SGAR-FGAR exposures and their 408 
timing have marked effects on toxicity,
44
 and deserve further attention from both an exposure 409 
pathway and potential effect standpoint.    410 
 Many investigations have documented AR exposure of invertebrates feeding on bait, and 411 
perhaps even small mammal feces, rodent carcasses and soil-bound AR residues.  Their hazard to 412 
insectivorous birds and mammals has yielded mixed findings as only a small fraction of the 413 
invertebrate food base may be exposed in a treated area.
91, 113-116
  However, some suggest that 414 
ecological communities often contain both larger numbers of individuals and more species of 415 
insectivorous vertebrates compared to top-level vertebrate predators, and thus AR-contaminated 416 
invertebrates might actually pose a greater risk to this feeding guild than previously thought.
117
  417 
A significant data gap remains for insectivorous vertebrates, some of which may be ecologically 418 
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vulnerable in island eradication projects.
118,119
   419 
 In contrast to the aforementioned terrestrial exposure pathway, there is now evidence that 420 
warfarin, at nanogram per liter quantities, is detectable in some wastewater effluents.
120
   Its 421 
source is presumed to be of human origin.  However, based on both its low concentration and log 422 
Kow  (2.37), it is highly unlikely that this is a significant source of exposure for predatory wildlife.  423 
Macromolecular to Population-Level Effects.  Remarkable differences in AR sensitivity have 424 
been reported in some omnivorous and predatory birds compared to commonly tested avian 425 
granivores.
 39,42,72,110
  Although inter-specific variation in VKOR activity and AR metabolism 426 
may account for these observations,
22
  there remains a need  for additional comparative toxicity 427 
and metabolism data for predatory species.  Furthermore, the relative in vitro potency of various 428 
ARs to VKOR,
121
 and their use in additive toxicity models (e.g., toxic units or equivalents) 429 
should be further examined as it could serve as an alternative method reducing the need for some 430 
in vivo testing.  It might be possible to screen for AR sensitivity of predatory wildlife by cross-431 
species comparison of the primary structure of VKOR to that found in resistant target species, as 432 
has been done for the arylhydrocarbon and steroid hormone receptors, and other ligand binding 433 
sites.
122-124
  However, such predictions do not account for interspecific differences in AR 434 
absorption, distribution, metabolism and elimination.  While the role of vitamin K deficiency in 435 
hemorrhagic syndrome in chickens, and warfarin sensitivity and resistance in rats, has been 436 
studied in great detail,
 125
 vitamin K status has not been evaluated in predatory wildlife, and 437 
could be a major factor in AR susceptibility and tolerance.   438 
Controlled AR exposure studies have principally focused on overt signs of toxicity and 439 
mortality, occasionally included measurement of AR residues and sublethal responses (e.g., 440 
behavior, condition, histopathology), and rarely quantification of blood clotting.
 72,80,126
  There 441 
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are key issues and even deficiencies in such  studies, including the use of artificial test conditions 442 
(e.g., no-choice continuous feed scenarios), and that spontaneous hemorrhage in AR-exposed 443 
animals is a “multi-causative phenomena” affected by stress and other variables.127  Many of 444 
these controlled studies failed to measure AR ingestion rate and concentration of residues in 445 
tissue that are needed to derive dietary- and tissue-based toxic reference values, and to estimate 446 
internal dose for modeling toxicokinetics.   447 
 A longstanding issue related to ARs, and environmental contaminants in general, is the 448 
significance of sublethal effects.  As illustrated in the AOP (Figure 1), several responses may 449 
have hypothetical, plausible, or established linkages foreshadowing higher order organismal or 450 
even population-level effects.  Based on existing data, predatory wildlife exposed to ARs either 451 
survive, with seemingly little or no direct long-term consequences, or they die.  Alternatively, it 452 
is certainly possible that the proximate cause of death of an individual seemingly unrelated to 453 
poisoning might ultimately have been triggered by AR residues and coagulopathy.  This may be 454 
responsible for the absence of clear dose-response relationships.  For example, a detailed 455 
analysis of birds of prey admitted to a veterinary clinic revealed that while 86% of 161 raptors 456 
contained AR residues, only 6% could be diagnosed as having succumbed from AR toxicosis.
12
  457 
No significant relation between liver brodifacoum residues and death was found, although the 458 
small number of individuals that died from causes other than trauma may have confounded this 459 
analysis.
12
  Nonetheless, some contend that AR exposure is one of many chemical insults 460 
affecting “condition” (e.g., lethargy could impair hunting, loss of body mass could reduce energy 461 
stores during winter), susceptibility to disease, resilience (e.g., recovery from non-fatal 462 
collisions, accidents and trauma), tolerance to extreme weather, and even sensitivity to other 463 
toxicants (e.g., Pb that can result in anemia), and could exacerbate blood loss during molt.  This 464 
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impaired condition hypothesis remains challenging to test and resolve.   465 
 There is some evidence that SGARs are one of several factors (e.g., low food availability 466 
with the shift to intensive farming, road mortality, loss of roost sites) that may be responsible for 467 
declining populations of some species of predatory birds.
65,77
  Based on extensive personal 468 
observations over a 21-year period (but not formal surveys), a decline in numbers of breeding 469 
pairs of raptors, and some circumstantial evidence of secondary AR poisoning, was noted with 470 
initiation of Klerat® (active ingredient brodifacoum) use on sugar-cane in Queensland, 471 
Australia.
57
  Recent studies examined barn owl reproduction at oil palm plantations in Malaysia 472 
that were baited with warfarin or brodifacoum
58
 and bromadiolone or chlorophacinone.
59
  Over 473 
several breeding cycles, both owl hatching and fledging success in treated plots were 474 
significantly lower compared to the reference area.  It was suggested that impaired reproductive 475 
performance was due to sublethal AR exposure of adults and nestlings, although confounding 476 
effects of reduced rat populations on reproductive parameters could not be discounted.  Clearly, 477 
the direct and indirect consequences and uncertainties of ARs on reproduction and population 478 
responses in predatory species deserve further attention.  479 
Exposure and Mortality Incidents.  Some suggest that AR risk to predatory birds and 480 
mammals has been overestimated, with the proportion of mortality being quite low in 481 
comparison to actual use.
3,69
  Anecdotal reports favor solitary events (e.g., death of a snowy owl, 482 
Nyctea scandiaca, which established residence near a correctional facility using 0.2% 483 
diphacinone tracking powder, with stomach contents full of rat remains).
52
  Likewise, in 484 
agricultural settings, the risk to non-target wildlife is generally perceived to be minimal
3,127
 as 485 
the vast majority of applications involve FGARs on croplands and fields for grazing livestock.  486 
However, baits with the SGAR bromadiolone or the FGAR chlorophacinone have been 487 
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responsible for some mortality of predatory and scavenging wildlife in France.
 51,74,94
 For 488 
eradication efforts involving introduced species on remote islands, practical experience has 489 
demonstrated that some projects create a surplus of readily available dead and dying rodents that 490 
can cause significant mortality of predatory birds (e.g., mortality of bald eagles and ravens with 491 
brodifacoum use on Langara Island, British Columbia;
106
 carcasses and remains of 46 bald eagles 492 
associated with brodifacoum application on Rat Island, Alaska
75
).  These findings demonstrate 493 
that patterns of AR use for control of commensal rodents and introduced species can result in a 494 
range of consequences.   495 
Perhaps the greatest unknowns are quantitative estimates of the magnitude of non-target 496 
predator mortality associated with AR use.  Few rigorously designed field trials have focused on 497 
FGAR or SGAR exposure and effects on predators,
3,128
 although two radiotelemetry studies 498 
generated some survival data which identified brodifacoum as a significant hazard to raptors in 499 
orchards.
129,130
  In a more recent study, risk predictions suggested that bromadiolone application 500 
for control of the water vole (Aricola terrestris) posed a significant hazard to red kites.
94
  While 501 
field surveys of the treated area detected three dead kites, and one moribund individual with 502 
clinical signs suggestive of AR exposure, residue concentrations did not confirm bromadiolone 503 
poisoning.  Use of banding and radiotelemetry techniques with insectivorous and predatory birds 504 
during efforts to eradicate introduced species in New Zealand have documented mortality 505 
associated with some formulations of brodifacoum (e.g., insectivorous weka on Ulva Island;
72
 506 
morepork, Ninox novaseelandiae on Mokoia Island
131
).  The vast majority of efforts to monitor 507 
AR effects on predators during field applications and eradication projects have entailed direct 508 
count observations, call counts, and carcass searches, all of which have varying degrees of 509 
inherent bias.  While exposure of non-target wildlife to ARs used for commensal rodent control 510 
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is well-documented in urban and suburban settings,
12,56
 overall effects on population dynamics 511 
have not been addressed.  More rigorous efforts in monitoring of non-target mortality should be 512 
routinely incorporated into pest control and eradication projects, assessing both short-term and 513 
long-term impacts to predatory species.   514 
 More extensive monitoring efforts on the magnitude of non-target predator mortality could 515 
add to our ability to gauge the overall effects of new risk mitigation measures.  Wildlife exposure 516 
and mortality incident schemes (e.g., Ecological Incident Information System of the U.S. EPA, 517 
the Predatory Bird Monitoring Scheme and the Wildlife Incident Investigation Scheme of the 518 
UK, and Wildlife Disease Surveillance System in France) have been the primary source of 519 
wildlife exposure data to date.  However, the relationship among AR residues and their relative 520 
potencies, sublethal effects, and mortality are poorly defined and difficult to extrapolate between 521 
species.
12,60
  Hepatic AR residues bound to high affinity and low affinity sites are not always a 522 
proxy of recent exposure or effect,
132,133
 and in some instances pathological evaluations are 523 
incomplete, and potentially compromised by disease and post-mortem storage conditions.
53
   524 
Resistance. Genetic-based resistance to FGARs and SGARs in commensal rodents has been 525 
documented in numerous locations,
8,9,29,30 
and it has been suggested to be a factor that could 526 
theoretically impact exposure of predatory wildlife.
60
  There is no formally published evidence 527 
that resistant rodents accumulate greater body burdens of ARs compared to sensitive 528 
individuals.
31,134,135 
 However, compared to dead and often concealed rats,
73
 the survival of AR-529 
exposed resistant individuals for extended periods might enhance the likelihood of secondary 530 
poisoning of predators.
60,134,135   
The role of resistance in mediating exposure, risk and even 531 
adaptation of non-target species has not been adequately evaluated.  532 
 533 
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ALTERNATIVES 534 
While not the intent of this review, it is worth noting that in addition to AR registration and label 535 
restrictions, there are multiple activities that attempt to minimize or prevent exposure and 536 
adverse effects to non-target wildlife.  Some large commercial users of rodenticides (e.g., Wal-537 
Mart) have shown leadership in implementing such measures.
136
  For large-scale applications 538 
and eradication projects, these include carcass removal accompanied by appropriate disposal, 539 
raptor capture and hold/relocation, hazing, and in some situations seasonal timing of baiting to 540 
reduce exposure of migratory species.  For smaller scale activities, education and outreach 541 
programs foster appropriate AR use (e.g., integrated pest management that includes habitat 542 
alteration, sanitation, exclusion of commensal pest species) and other practices (e.g., concealing 543 
bait to minimize non-target exposure, carcass disposal, removing bait at end of treatment).
137,138
  544 
On a global scale, the number of registered vertebrate pesticides has actually “plummeted” over 545 
the last 50 years, with few newly registered compounds.
82
  There are some acute vertebrate 546 
pesticides (e.g., bromethalin, cholecalciferol, zinc phosphide) for which secondary poisoning 547 
potential of non-target wildlife is low, but these compounds show high acute toxicity, lack 548 
specific antidotes and may not be suitable for use in close proximity to man, while other 549 
compounds (e.g., sodium fluoroacetate, strychnine) lack effective antidotes and are considered 550 
inhumane.  Recent research and development efforts have resulted in registration of para-551 
aminopropiophenone in 2011
105
 for control of larger pest species (stoats and weasels) in New 552 
Zealand.  In addition, the combination of an FGAR and acute vertebrate pesticide (e.g., 553 
coumatetralyl + cholecalciferol) was at one time used in Germany
139
 and is now undergoing 554 
trials for potential registration in New Zealand.
105
 Other innovations include new delivery 555 
systems and bait coatings,
105
  although their effectiveness has not been completely evaluated in 556 
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the field.   Biological controls, such as attracting raptors to predate rodents,
140,141
  interaction of 557 
pathogens to reduce AR doses in baits,
142
 and use of the highly pathogenic protozoan Sarcocystis 558 
singaporensis to debilitate rodents,
143
 have been advocated by some, but do not result in rodent 559 
elimination. 560 
 561 
CONCLUSIONS 562 
Anticoagulant rodenticides are one of the principal vertebrate pesticides for the control of 563 
commensal rodents that damage crops and food stores, and cause health issues, as well as for the 564 
eradication of invasive species to restore biodiversity to oceanic islands.  By constructing an 565 
AOP for ARs as they relate to non-target predatory species, it is apparent that the “mechanism of 566 
action” from the molecular through cellular levels of organization is well-understood.  However, 567 
our knowledge of the linkages and forecasting of responses at the level of the individual 568 
(behavioral, physiological, survival) through population (recruitment) is incomplete for this well-569 
studied class of vertebrate pesticide agents.  Effects of ARs on predatory birds and mammals at 570 
the population level have not been conclusively established.  Our knowledge of the hazard 571 
associated with resistance development, that could potentially increase AR concentrations in 572 
target species, is inadequate.  At these higher levels of biological organization, our understanding 573 
is less complete and characterized as “mode of action”,17 which is the case for many classes of 574 
pesticides and environmental contaminants.  While we have identified numerous information 575 
needs, perhaps the most critical uncertainties related to AR risks to non-target wildlife include (i) 576 
more complete understanding of exposure pathways, (ii) comparative sensitivity among 577 
predatory species, (iii) the relation among residues of multiple ARs, their relative potency, and 578 
combined effect at the level of the individual, (iv) quantitative estimates of mortality, particularly 579 
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in light of new regulations that attempt to mitigate adverse effects, (v) identification of the 580 
occurrence of sublethal effects and their higher-tier population and long-term ecological 581 
consequences, and (vi) the effects of multiple low-level AR exposures.  582 
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